Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...